Medicine and HealthNature Communications
A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge
Y. Yahalom-ronen, H. Tamir, et al.
This study introduces an innovative VSV-ΔG-spike vaccine to combat SARS-CoV-2, developed by a team from the Israel Institute for Biological Research. The vaccine demonstrated strong safety and efficacy, inducing neutralizing antibodies and providing protection in animal models, showcasing its potential as a robust defense against COVID-19.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
J. Logue, R. M. Johnson, et al.
Medicine and Health
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
H. Ma, X. Zhang, et al.
Medicine and Health
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
W. Pang, Y. Lu, et al.
Medicine and Health
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
X. Zhang, H. Zhang, et al.
